Nonalcoholic fatty liver disease and liver transplantation.
10.3760/cma.j.cn501113-20201022-00574
- Author:
Wei Qi ZHANG
1
;
Yan XIE
2
;
Wen Tao JIANG
2
Author Information
1. Department of Liver Transplantation, the First Central College of Tianjin Medical University, Tianjin 300110, China.
2. Department of Liver Transplantation, Tianjin First Central Hospital, Tianjin 300192, China.
- Publication Type:Review
- MeSH:
End Stage Liver Disease;
Humans;
Liver Transplantation/adverse effects*;
Metabolic Syndrome;
Non-alcoholic Fatty Liver Disease/epidemiology*;
Prevalence
- From:
Chinese Journal of Hepatology
2022;30(4):439-442
- CountryChina
- Language:Chinese
-
Abstract:
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) is now the second largest indication for liver transplantation in Western countries, but viral hepatitis B and end-stage alcohol-related liver disease are still the main indications in China. With the improvement of people's living standards, the prevalence of metabolic syndrome, and the number of NAFLD patients has also gradually increased. At the same time, with the hepatitis B vaccination popularization and the nucleos(t)ide analogues and other drugs uses, it is predicted that NAFLD-related end-stage liver disease may become one of the main indications for liver transplantation in our country in the future. This article reviews the research progress of NAFLD and liver transplantation.
